DebraJeanKelshMD

Psychiatry • Kansas City, KS

Physician

Join to view full profile

Dr. Kelsh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kelsh's full profile

Already have an account?

Office
3901 Rainbow Blvd
Kansas City, KS 66160
Phone+1 913-588-1304

Fax+1 913-588-1310

Education & Training

University of Kansas School of MedicineResidency, Psychiatry, 1992 - 1996
University of Kansas School of MedicineResidency, Internal Medicine, 1991 - 1991
University of Kansas School of MedicineClass of 1991

Certifications & Licensure

KS State Medical License 1995 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2011 Jan 17
Completed
Phase 3
Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers Start of enrollment: 2016 Jul 01
Completed
Phase 1
Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers Start of enrollment: 2017 Jun 01
Completed
Phase 1
Comparison of Naloxone Pharmacokinetics Start of enrollment: 2018 Jan 03
Completed
Phase 1
Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam Start of enrollment: 2017 Dec 04
Completed
Phase 1
Evaluation of Abuse Liability of Very Low Nicotine (VLN) Mentholated Cigarettes Start of enrollment: 2018 May 01
Completed
Phase 1
Evaluation of the Abuse Liability of Very Low Nicotine (VLN) Cigarettes Start of enrollment: 2018 Apr 13
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABAreceptor, and morphine...
Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo
Journal of Psychopharmacology. 2023-05-01
1 citations
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.
Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo
Journal of Psychopharmacology. 2023-02-01
4 citations
Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate.
Megan J Shram, Beatrice Setnik, Lynn Webster, Sven Guenther, Travis C Mickle
Current Medical Research and Opinion. 2022-07-01